Salipro Biotech
- Company typePrivate
- Founded2016
- HeadquartersStockholm, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Salipro Biotech does
Salipro Biotech AB is a privately held Swedish biotech company founded in 2016 as a spinout from Karolinska Institutet, headquartered in Stockholm. The company develops and commercializes the proprietary Salipro® platform, a nano-membrane technology that stabilizes membrane proteins in their native-like, detergent-free lipid environment. The platform enables drug discovery workflows against challenging targets — GPCRs, ion channels, and SLC/ABC transporters — that are inherently unstable outside the cell membrane and historically considered difficult or undruggable. Application areas include DNA-Encoded Library (DEL) screening, antibody discovery (phage display, immunization, B cell sorting), cryo-EM structure determination, and SPR binding studies (Biacore).
Salipro operates an asset-light, B2B partnership model rather than developing its own therapeutics. Revenue is generated through fee-for-service research collaborations, multi-target platform licensing agreements, and strategic partnerships with pharmaceutical, biotechnology, and crop protection companies. Deal economics typically include upfront payments, milestone payments on technical or commercial achievements, and potential downstream royalties; the company highlights option exercises (e.g., Boehringer Ingelheim) and milestone triggers (e.g., Sanofi) as evidence of contract progression. GTM is sales-led and direct, executed by a small business development team across global pharma hubs.
The company's value proposition rests on a defensible intellectual property estate (60+ granted patents across the U.S., EU, China, Japan, Australia, and Singapore, extending to 2042), scientific validation through 60+ peer-reviewed publications in journals such as Cell, Nature, and Science, and a growing roster of named partners including Boehringer Ingelheim, Sanofi, AstraZeneca, Bio-Rad, Daewoong Pharmaceutical, Sumitomo Pharma, Icosagen, and ATEM. A 2024 milestone of 50+ collaborative research programs and a 2025-2026 acceleration of multi-target deals with Top 5 and Top 10 global pharma companies indicate an expanding partnership pipeline across pharma, biotech, ag-chem, and emerging modalities such as gene therapy.
Salipro Biotech firmographics
Firmographics- Name
- Salipro Biotech
- Legal name
- Salipro Biotech AB
- Website
- https://salipro.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Salipro Biotech industry classification
Industry- Product category
- Drug Discovery Platform Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Salipro Biotech is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Salipro Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Research Collaborations: Fee-for-service research collaborations with pharma and biotech companies where Salipro provides access to its platform technology for drug discovery programs against specific membrane protein targets. These typically involve upfront payments, milestone payments, and potential downstream royalties.
- Licensing Agreements: Platform technology licensing deals with pharmaceutical partners, including multi-target research agreements and research/license agreements that may include option exercises, milestone payments, and royalties on successful drug development.
- Strategic Partnerships: Deep partnerships with major pharmaceutical companies involving multiple targets, potentially including equity considerations, co-development arrangements, and co-commercialization rights.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Salipro Biotech product offering
Product offeringCore offering
Salipro Biotech provides a proprietary Salipro® nano-membrane platform technology that stabilizes membrane proteins in their native-like, detergent-free lipid environment to enable drug discovery against challenging targets such as GPCRs, ion channels and SLC transporters. The company monetizes the platform through fee-for-service research collaborations and licensing agreements with top-tier pharmaceutical and biotechnology companies, supporting antibody discovery, small molecule screening (including DNA-Encoded Library screening), SPR binding analysis, and cryo-EM structure determination.
Product overview
Salipro Biotech offers the Salipro® platform as its core proprietary technology, a nano-membrane platform that stabilizes membrane proteins in native-like, detergent-free lipid nanoparticles. The platform comprises the main Salipro® Platform technology and its Salipro® DirectMX™ submodule for direct membrane extraction. Multiple application-specific workflows extend the platform: Salipro® for Antibody Discovery (covering phage display, immunization, B cell sorting, and antibody characterization), Salipro® for Discovery of Small Molecules (DNA-Encoded Library DEL screening with SPR validation and cryo-EM hit optimization), Salipro® for SPR/Biacore Studies, Salipro® for cryo-EM structural determination, and Salipro® for Immunization and B Cell Sorting. Together, these enable drug discovery against challenging targets including GPCRs, ion channels, SLC transporters, and ABC transporters. The company operates exclusively through research collaborations with pharma and biotech partners rather than as a direct-to-consumer product.
Differentiator
Problem solved
Functional benefit
Brands
- Salipro®: Proprietary nano-membrane platform technology that stabilizes membrane proteins for drug discovery applications
- Salipro® DirectMX™
Products and services
- Salipro® Platform Proprietary nano-membrane platform technology that stabilizes membrane proteins in their native lipid environment within detergent-free lipid nanoparticles, enabling drug discovery workflows for therapeutic antibodies and small molecules against challenging targets such as GPCRs, ion channels, and SLC transporters. Sold to enterprise pharma and biotech partners via research collaborations and licensing agreements.
- Salipro® DirectMX™ Enables direct reconstitution of membrane proteins from crude cell membranes into Salipro® particles with native lipids, bypassing the need for prior purification and preserving the protein in its natural lipid environment. Sold as part of the Salipro® platform offering to pharma and biotech partners.
- Salipro® for Antibody Discovery Application-specific Salipro® offering for stabilization of challenging membrane protein targets (GPCRs, ion channels) in nanoparticles used in phage display, immunization, B cell sorting, and antibody characterization workflows for therapeutic antibody discovery. Targeted at pharma and biotech partners.
- Salipro® for Discovery of Small Molecules (DEL) Application of Salipro®-stabilized membrane proteins in DNA-Encoded Library screening workflows for rapid identification of small molecule drug candidates against challenging targets, combined with SPR hit validation and cryo-EM optimization. Targeted at pharma and biotech drug discovery teams.
- Salipro® for SPR/Biacore Studies Salipro®-enabled surface plasmon resonance (SPR) binding analysis on Biacore systems in a detergent-free environment, supporting ligand binding affinity and kinetics studies of membrane protein targets. Provided to pharma and biotech drug discovery researchers.
- Salipro® for Cryo-EM Structure Determination Generation of high-quality membrane protein samples (e.g., Pannexin 1) in Salipro® particles suitable for cryo-electron microscopy structure determination, capturing multiple functional states and enabling structure-based drug design for pharma and biotech partners.
Quantifiable outcome
- 50+ collaborative research programs established with pharma and biotech partners
- +3 more outcomes
Companies that use Salipro Biotech
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
Salipro Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability2 records
Feature5 records
Salipro Biotech partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered supporting and core.
- Gene Therapy Biotech Company (USA)supportingResearch collaboration where Salipro® platform will be used to evaluate therapeutic antibodies to improve cell-based gene therapies. Supports core mission of making the undruggable druggable.
- Next-Generation Biotech Company (USA)supportingNew research collaboration using Salipro® platform in combination with company's Machine Learning platform to develop drug candidates against a GPCR target.
- ATEMsupportingCryo-EM epitope mapping collaboration enabling structural insight into antibody-target interactions. Combined with Salipro® stabilization and Bio-Rad's Pioneer platform for end-to-end antibody discovery workflow against challenging GPCR targets like CXCR4.
- Global Top 5 Pharmaceutical Company (USA)coreMulti-target collaboration agreement leveraging Salipro Biotech's expertise and proprietary technology (Salipro®) to stabilise challenging drug targets including GPCRs, ion channels and transporters, making them accessible for development of next-generation therapeutics.
- AstraZenecacoreCollaborative research enabling DNA-Encoded Library (DEL) screening on membrane proteins using the Salipro® platform. Research used Pannexin 1 (PANX1) channel as model system to screen millions of compounds and identify novel binders validated through structural, biophysical, and functional assays. Study establishes proof-of-concept for applying DEL screening to complex membrane proteins.
- University of CopenhagencoreAcademic research collaboration contributing to the DEL screening research published in Nature Scientific Reports. Provided expertise in membrane protein biology and functional assays for validation of novel binders.
- Boehringer IngelheimcoreResearch and License Agreement for Salipro®-enabled drug discovery programs. Boehringer Ingelheim exercised its option for a Salipro®-enabled target, marking important progression in the collaboration aimed at enabling novel drug discovery through Salipro's proprietary membrane protein stabilization technology.
- Daewoong PharmaceuticalsupportingResearch collaboration combining Salipro Biotech's expertise and Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for generation of small molecule drugs. First collaboration with a partner in South Korea.
- Top 10 Global Pharma CompanycoreAdditional collaboration with one of the Top 10 global pharma companies leveraging proprietary Salipro® platform technology. Partnership focuses on an exciting drug target from internal pipeline, aiming to unlock new therapeutic possibilities.
- Bio-Rad LaboratoriescoreAntibody discovery collaboration leveraging Salipro® platform with Bio-Rad's Pioneer™ Antibody Discovery Platform. Successfully developed CXCR4-targeting antibodies with affinities similar to or exceeding ulocuplumab, demonstrating functional activity and potential for new therapeutic avenues in immuno-oncology.
- Top 5 Crop Protection CompanysupportingMulti-target research collaboration exploring potential of Salipro® platform to unlock challenging agricultural targets and evaluate novel solutions for crop protection strategies. Additional Top 5 crop protection company collaboration announced.
- SanoficoreCollaboration and licensing agreement achieving de novo high-resolution cryoEM structures of Salipro®-embedded GPCR in complex with biologics, as well as in vitro binding assays for interaction affinity determination, triggering milestone payments.
- IcosagensupportingMulti-target antibody research agreement for discovery and characterization of monoclonal antibodies against GPCRs and SLC transporters. Combines Salipro's platform technology with Icosagen's QMCF technology and protein analytics capabilities.
- Sumitomo PharmasupportingResearch collaboration to advance a drug discovery program using Salipro® platform for stabilizing challenging membrane proteins. Expands multi-target research collaboration with top-10 Japanese pharmaceutical company.
- DyNABindcoreCollaboration to enable DEL (DNA-Encoded Library) screening for membrane proteins using the Salipro® platform. DyNABind contributed expertise in DNA-encoded library technology for small molecule discovery against challenging membrane protein targets.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Salipro Biotech competitors and assessment
Company assessmentBroad incumbents
- Cytiva (Danaher): Broad life sciences tools vendor offering Biacore SPR systems, chromatography resins, and protein purification products used in the same drug discovery workflows Salipro supports. Overlaps as a complementary incumbent supplier rather than a direct membrane-protein competitor.
- Sartorius: Large bioprocessing and bioanalytics supplier serving pharma and biotech R&D and manufacturing. Overlaps with Salipro at the customer interface but operates at vastly greater scale across a much wider product portfolio.
- Thermo Fisher Scientific: Global life sciences tools and pharma services giant with broad offerings in protein research, cryo-EM, structural biology and drug discovery services. Adjacent incumbent that competes for budget on similar pharma R&D workflows.
Emerging players
- Nanion Technologies: Provides electrophysiology and membrane protein screening instrumentation for ion channel and transporter drug discovery. Adjacent competitor in functional characterization of membrane protein targets.
- NanoTemper Technologies: Offers protein stability and binding characterization tools (DSF, MST) widely used alongside membrane protein workflows. Comparable as an enabling tools provider for challenging protein targets, including biologics discovery.
Others
- WuXi AppTec: Large CRO/CDMO providing drug discovery and development services including protein production and structural biology. Compares to Salipro only indirectly as an alternate path pharma partners can use to access membrane protein-enabled research.
Direct peers
- Avanti Polar Lipids: Manufactures high-purity lipids and lipid-based reagents widely used in membrane protein research and drug delivery. Comparable as a supplier into membrane protein workflows, though less vertically integrated around a single platform.
- Calixar: Specializes in membrane protein stabilization and sample preparation for structural biology and drug discovery (notably acquired by Sanofi). Direct competitor in enabling difficult membrane protein targets for SBDD and cryo-EM workflows.
- Anatrace (Promega): Supplies detergents, lipids and reagents specifically designed for membrane protein research and stabilization. Sells into the same pharma and academic structural biology buyer that Salipro serves with its platform technology.
- Cube Biotech: Provides membrane protein stabilization and extraction tools including SMALPs and nanodiscs used in drug discovery and structural biology. Closely comparable to Salipro's core lipid-nanoparticle stabilization offering for GPCRs and other membrane targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Salipro Biotech social profiles
Digital presenceSalipro Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Salipro Biotech leadership team
Management profileNumber of profiles
Profiles6 records
Salipro Biotech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Salipro Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Salipro Biotech
What does Salipro Biotech do?
Salipro Biotech provides a proprietary Salipro® nano-membrane platform technology that stabilizes membrane proteins in their native-like, detergent-free lipid environment to enable drug discovery against challenging targets such as GPCRs, ion channels and SLC transporters. The company monetizes the platform through fee-for-service research collaborations and licensing agreements with top-tier pharmaceutical and biotechnology companies, supporting antibody discovery, small molecule screening (including DNA-Encoded Library screening), SPR binding analysis, and cryo-EM structure determination.
Is Salipro Biotech a public or private company?
Salipro Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Salipro Biotech founded?
Salipro Biotech was founded in 2016. It employs 1 to 10 people.
Where is Salipro Biotech based?
Salipro Biotech is headquartered in Stockholm, Sweden, in the Europe region.
How does Salipro Biotech make money?
Three revenue lines are on record. Research Collaborations are the primary driver. The others are licensing Agreements and strategic Partnerships.
Who are Salipro Biotech's main competitors?
Broad incumbents on record are Cytiva (Danaher), Sartorius and Thermo Fisher Scientific. Emerging players are Nanion Technologies and NanoTemper Technologies. WuXi AppTec is listed as an others. Direct peers are Avanti Polar Lipids, Calixar, Anatrace (Promega) and Cube Biotech.
Does Salipro Biotech have an API?
No public API is recorded for Salipro Biotech.
What industry is Salipro Biotech in?
Salipro Biotech's product category is Drug Discovery Platform Technology. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714.